{"title":"免疫缺陷的生化意义:肿瘤患者的监测","authors":"Tsuneo Kobayashi","doi":"10.21767/2254-6081.100174","DOIUrl":null,"url":null,"abstract":"Background: For a long time, phenomenon of defective immune-surveillance in cancer patients from pathological standpoint was not elucidated. I have reported 1985 that lowering seral cyclic AMP is biochemical reason of defective immunesurveillance from adoptive lymphocyte immunotherapy experiment among cancer patients. Recently, Honjo Tasku et al., reported why T cell don’t attack cancer cells by the covering of PD-L1 on its receptor of PD-1. This is also one of defective immune-surveillance from cellular side. I have recently surveyed the correlation between seral cyclic AMP concentration and immune activity in cancer patients. I have confirmed the biochemical reason of lowering cyclic AMP leads to seral defective immune-surveillance in cancer patient’s serum. Methods: I have surveyed seral cyclic AMP concentration and T cell number and NK cell among 40 cancer patients and preclinical cancer patients. Results: The averaged seral cyclic AMP has a positive tendency between lower immune activity and lower cyclic AMP in the serum when cancer is developing beforehand. Conclusion: As cyclic AMP is elevated after fasting therapy, adoptive lymphocyte immunotherapy become useful as immuno-potentiation even if in advanced cancer patients.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100174","citationCount":"1","resultStr":"{\"title\":\"Biochemical Meaning of Defective Immune:Surveillance in Cancer Patients\",\"authors\":\"Tsuneo Kobayashi\",\"doi\":\"10.21767/2254-6081.100174\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: For a long time, phenomenon of defective immune-surveillance in cancer patients from pathological standpoint was not elucidated. I have reported 1985 that lowering seral cyclic AMP is biochemical reason of defective immunesurveillance from adoptive lymphocyte immunotherapy experiment among cancer patients. Recently, Honjo Tasku et al., reported why T cell don’t attack cancer cells by the covering of PD-L1 on its receptor of PD-1. This is also one of defective immune-surveillance from cellular side. I have recently surveyed the correlation between seral cyclic AMP concentration and immune activity in cancer patients. I have confirmed the biochemical reason of lowering cyclic AMP leads to seral defective immune-surveillance in cancer patient’s serum. Methods: I have surveyed seral cyclic AMP concentration and T cell number and NK cell among 40 cancer patients and preclinical cancer patients. Results: The averaged seral cyclic AMP has a positive tendency between lower immune activity and lower cyclic AMP in the serum when cancer is developing beforehand. Conclusion: As cyclic AMP is elevated after fasting therapy, adoptive lymphocyte immunotherapy become useful as immuno-potentiation even if in advanced cancer patients.\",\"PeriodicalId\":91204,\"journal\":{\"name\":\"Archives in cancer research\",\"volume\":\"6 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.21767/2254-6081.100174\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives in cancer research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21767/2254-6081.100174\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives in cancer research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21767/2254-6081.100174","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Biochemical Meaning of Defective Immune:Surveillance in Cancer Patients
Background: For a long time, phenomenon of defective immune-surveillance in cancer patients from pathological standpoint was not elucidated. I have reported 1985 that lowering seral cyclic AMP is biochemical reason of defective immunesurveillance from adoptive lymphocyte immunotherapy experiment among cancer patients. Recently, Honjo Tasku et al., reported why T cell don’t attack cancer cells by the covering of PD-L1 on its receptor of PD-1. This is also one of defective immune-surveillance from cellular side. I have recently surveyed the correlation between seral cyclic AMP concentration and immune activity in cancer patients. I have confirmed the biochemical reason of lowering cyclic AMP leads to seral defective immune-surveillance in cancer patient’s serum. Methods: I have surveyed seral cyclic AMP concentration and T cell number and NK cell among 40 cancer patients and preclinical cancer patients. Results: The averaged seral cyclic AMP has a positive tendency between lower immune activity and lower cyclic AMP in the serum when cancer is developing beforehand. Conclusion: As cyclic AMP is elevated after fasting therapy, adoptive lymphocyte immunotherapy become useful as immuno-potentiation even if in advanced cancer patients.